{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:11:54Z","timestamp":1793398314217,"version":"4.5.0"},"reference-count":103,"publisher":"Georg Thieme Verlag KG","issue":"08","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.<\/jats:p>","DOI":"10.1055\/s-0042-1756441","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T22:52:23Z","timestamp":1666047143000},"page":"845-861","source":"Crossref","is-referenced-by-count":16,"title":["Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I"],"prefix":"10.1055","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-1064","authenticated-orcid":false,"given":"Eliana Meire","family":"Melhado","sequence":"additional","affiliation":[{"name":"Centro Universit\u00e1rio Padre Albino, Faculdade de Medicina, Departamento de Neurologia, Catanduva SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-4164","authenticated-orcid":false,"given":"Paulo Sergio Faro","family":"Santos","sequence":"additional","affiliation":[{"name":"Instituto de Neurologia de Curitiba, Departamento de Neurologia, Setor de Cefaleia e Dor Orofacial, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-0735","authenticated-orcid":false,"given":"Alexandre Ottoni","family":"Kaup","sequence":"additional","affiliation":[{"name":"Houston Headache Clinic, Houston TX, United States."},{"name":"Universidade Federal de S\u00e3o Paulo, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."},{"name":"Universidade de Santo Amaro, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-8490","authenticated-orcid":false,"given":"Aline Turbino Neves Martins da","family":"Costa","sequence":"additional","affiliation":[{"name":"Hospital Santa Marcelina, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6056","authenticated-orcid":false,"given":"C\u00e9lia Aparecida de Paula","family":"Roesler","sequence":"additional","affiliation":[{"name":"Q2 Centro M\u00e9dico de Neurologia, Depto de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-0430","authenticated-orcid":false,"given":"\u00c9lcio Juliato","family":"Piovesan","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Departamento de Cl\u00ednica M\u00e9dica, Disciplina de Neurologia, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-1376","authenticated-orcid":false,"given":"Elder Machado","family":"Sarmento","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-2330","authenticated-orcid":false,"given":"Giselle Oliveira Martins","family":"Theotonio","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Centro de Pesquisas, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8689-6271","authenticated-orcid":false,"given":"Henrique Carneiro de","family":"Campos","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Neurol\u00f3gica, Belo Horizonte MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-340X","authenticated-orcid":false,"given":"Ida","family":"Fortini","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-2187","authenticated-orcid":false,"given":"Jano Alves de","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Departamento de Medicina Cl\u00ednica, Disciplina de Neurologia, Niter\u00f3i RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-9623","authenticated-orcid":false,"given":"Jayme Antunes","family":"Maciel J\u00fanior","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-3771","authenticated-orcid":false,"given":"Jo\u00e3o Batista Alves","family":"Segundo","sequence":"additional","affiliation":[{"name":"Centro Integrado de Sa\u00fade Lineu Ara\u00fajo, Ambulat\u00f3rio de Neurologia, Teresina PI, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-5552","authenticated-orcid":false,"given":"Jo\u00e3o Jos\u00e9 Freitas de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Unichristus, Curso de Medicina, Disciplina de Neurologia, Fortaleza CE, Brazil."},{"name":"Hospital Geral de Fortaleza, Servi\u00e7o de Neurologia, N\u00facleo de Cefaleias, Fortaleza CE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-6464","authenticated-orcid":false,"given":"Jos\u00e9 Geraldo","family":"Speziali","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neurologia, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-5789","authenticated-orcid":false,"given":"Leandro Cortoni","family":"Calia","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Escola Paulista de Medicina, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-9115","authenticated-orcid":false,"given":"Liselotte Menke","family":"Barea","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Disciplina de Neurologia, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-627X","authenticated-orcid":false,"given":"Luiz Paulo","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Catarina, Hospital Universit\u00e1rio, Servi\u00e7o de Neurologia, Florian\u00f3polis SC, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4841-4491","authenticated-orcid":false,"given":"Marcio Nattan Portes","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Depto de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3517-3238","authenticated-orcid":false,"given":"Marcos Ravi Cerqueira Ferreira","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Ant\u00f4nio Pedro, Servi\u00e7o de Neurologia, Niter\u00f3i RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-5566","authenticated-orcid":false,"given":"Maria Eduarda Nobre de Magalh\u00e3es","family":"Costa","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil."},{"name":"Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-1905","authenticated-orcid":false,"given":"M\u00e1rio Fernando Prieto","family":"Peres","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-9395","authenticated-orcid":false,"given":"Mauro Eduardo","family":"Jurno","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Jos\u00e9 Bonif\u00e1cio Lafayette de Andrada, Faculdade de Medicina de Barbacena, Barbacena MG, Brazil."},{"name":"Funda\u00e7\u00e3o Hospitalar do Estado de Minas Gerais, Hospital Regional de Barbacena Dr. Jos\u00e9 Am\u00e9rico, Barbacena MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6552-0379","authenticated-orcid":false,"given":"Patr\u00edcia Machado","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Secretaria de Estado da Sa\u00fade do Distrito Federal, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-7475","authenticated-orcid":false,"given":"Pedro Andr\u00e9","family":"Kowacs","sequence":"additional","affiliation":[{"name":"Instituto de Neurologia de Curitiba, Servi\u00e7o de Neurologia, Curitiba PR, Brazil."},{"name":"Universidade Federal do Paran\u00e1, Complexo Hospital de Cl\u00ednicas, Servi\u00e7o de Neurologia, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-2637","authenticated-orcid":false,"given":"Pedro Augusto Sampaio","family":"Rocha-Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, \u00c1rea de Neuropsquiatria, Recife PE, Brazil."},{"name":"Universidade de Pernambuco, Hospital Universit\u00e1rio Oswaldo Cruz, Ambulat\u00f3rio de Cefaleias, Recife PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-428X","authenticated-orcid":false,"given":"Pedro Ferreira","family":"Moreira Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Hospital Universit\u00e1rio Ant\u00f4nio Pedro, Departamento de Medicina Cl\u00ednica, Niter\u00f3i RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-9031","authenticated-orcid":false,"given":"Raimundo Pereira","family":"Silva-Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal do Par\u00e1, Bel\u00e9m PA, Brazil."},{"name":"Universidade do Estado do Par\u00e1, Bel\u00e9m PA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-089X","authenticated-orcid":false,"given":"Yara Dadalti","family":"Fragoso","sequence":"additional","affiliation":[{"name":"Universidade Metropolitana de Santos, Santos SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"07","key":"ref2","first-page":"509","article-title":"(2019). Consenso da Sociedade Brasileira de Cefaleia sobre o tratamento da migr\u00e2nea cr\u00f4nica [Consensus of the Brazilian Headache Society on the treatment of chronic migraine]","volume":"77","author":"F. Kowacs","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"03","key":"ref3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-2982.2006.01275.x","article-title":"Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study","volume":"27","author":"S Silberstein","year":"2007","journal-title":"Cephalalgia"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1468-2982.2008.01782.x","article-title":"A nationwide population-based study of migraine in Brazil","volume":"29","author":"L P Queiroz","year":"2009","journal-title":"Cephalalgia"},{"issue":"03","key":"ref5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study","volume":"47","author":"S Diamond","year":"2007","journal-title":"Headache"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: will health politicians now take notice?","volume":"19","author":"T J Steiner","year":"2018","journal-title":"J Headache Pain"},{"issue":"03","key":"ref8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.pharmthera.2010.12.001","article-title":"Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects","volume":"129","author":"K Y Chan","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1590\/S0004-282X2002000100030","article-title":"Brazilian Headache Society (Filiada \u00e0 International Headache Society). RECOMENDA\u00c7\u00d5ES PARA O TRATAMENTO PROFIL\u00c1TICO DA MIGR\u00c2NEA Consenso da Sociedade Brasileira de Cefal\u00e9ia","volume":"60","author":"Comit\u00ea AD Hoc da Sociedade Brasileira de Cefal\u00e9ia","year":"2002","journal-title":"Arq Neuropsiquiatr"},{"issue":"04","key":"ref11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11940-019-0556-3","article-title":"Beta-blockers for migraine prevention: a review article","volume":"21","author":"A Danesh","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"02","key":"ref12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11916-004-0022-z","article-title":"Prophylactic migraine therapy: mechanisms and evidence","volume":"8","author":"N M Ramadan","year":"2004","journal-title":"Curr Pain Headache Rep"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40263-017-0430-3","article-title":"Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine","volume":"31","author":"P Tfelt-Hansen","year":"2017","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2011.02.020","article-title":"The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine","volume":"305","author":"J H Min","year":"2011","journal-title":"J Neurol Sci"},{"issue":"03","key":"ref15","doi-asserted-by":"publisher","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"J L Jackson","year":"2019","journal-title":"PLoS One"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1742-1241.1983.tb08456.x","article-title":"Prophylactic propranolol in the treatment of headache","volume":"37","author":"T G Palferman","year":"1983","journal-title":"Br J Clin Pract"},{"key":"ref17","first-page":"263","article-title":"Propranolol in prophylaxis of migraine","volume":"82","author":"G K Ahuja","year":"1985","journal-title":"Indian J Med Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/03331024870070S6203","article-title":"Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo","volume":"7","author":"A Kuritzky","year":"1987","journal-title":"Cephalalgia"},{"issue":"17","key":"ref19","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1","volume":"78","author":"S D Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1212\/WNL.44.4.647","article-title":"Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study","volume":"44","author":"R Jensen","year":"1994","journal-title":"Neurology"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0404.2008.01087.x","article-title":"A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis","volume":"118","author":"F Ashtari","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"08","key":"ref22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","article-title":"Topiramate in migraine prophylaxis\u2013results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"H C Diener","year":"2004","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: Their new life from hypertension to cancer and migraine","volume":"151","author":"C Fumagalli","year":"2020","journal-title":"Pharmacol Res"},{"issue":"S 01","key":"ref24","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1007\/s10072-011-0526-3","article-title":"Migraine prophylaxis: what is new and what we need?","volume":"32","author":"P Barbanti","year":"2011","journal-title":"Neurol Sci"},{"issue":"04","key":"ref25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1046\/j.1468-2982.1983.0304207.x","article-title":"Prophylactic treatment of classical and non-classical migraine with metoprolol\u2013a comparison with placebo","volume":"3","author":"P G Andersson","year":"1983","journal-title":"Cephalalgia"},{"issue":"04","key":"ref26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1468-2982.1987.0704231.x","article-title":"Classic migraine: effective prophylaxis with metoprolol","volume":"7","author":"P Kangasniemi","year":"1987","journal-title":"Cephalalgia"},{"issue":"01","key":"ref27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2524.1988.hed2801015.x","article-title":"Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up","volume":"28","author":"T J Steiner","year":"1988","journal-title":"Headache"},{"issue":"09","key":"ref28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/j.1468-2982.2007.01377.x","article-title":"Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study","volume":"27","author":"M Siniatchkin","year":"2007","journal-title":"Cephalalgia"},{"issue":"02","key":"ref29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1526-4610.1985.hed 2502107.x","article-title":"Clomipramine and metoprolol in migraine prophylaxis\u2013a double-blind crossover study","volume":"25","author":"H D Langohr","year":"1985","journal-title":"Headache"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1468-2982.1984.0402091.x","article-title":"Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study","volume":"4","author":"P Kangasniemi","year":"1984","journal-title":"Cephalalgia"},{"issue":"18","key":"ref31","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.1984.03350180030025","article-title":"Migraine prevention with timolol. A double-blind crossover study","volume":"252","author":"S Stellar","year":"1984","journal-title":"JAMA"},{"issue":"01","key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.1984.tb07772.x","article-title":"Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial","volume":"69","author":"P Tfelt-Hansen","year":"1984","journal-title":"Acta Neurol Scand"},{"issue":"04","key":"ref33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1526-4610.1983.hed2304188.x","article-title":"Atenolol for migraine prophylaxis","volume":"23","author":"B Forssman","year":"1983","journal-title":"Headache"},{"issue":"07","key":"ref34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1526-4610.1987.hed2707372.x","article-title":"Atenolol in migraine prophylaxis a double-blind cross-over multicentre study","volume":"27","author":"V Johannsson","year":"1987","journal-title":"Headache"},{"key":"ref35","first-page":"37","article-title":"Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine","volume":"31","author":"P Stensrud","year":"1980","journal-title":"Ups J Med Sci Suppl"},{"issue":"08","key":"ref36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1526-4610.1987.hed2708421.x","article-title":"Comparative efficacy of nadolol and propranolol in the management of migraine","volume":"27","author":"A Sudilovsky","year":"1987","journal-title":"Headache"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/08038020410016548","article-title":"Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients","volume":"1","author":"A Zanchetti","year":"2004","journal-title":"Blood Press Suppl"},{"issue":"S 03","key":"ref38","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00005344-200112003-00006","article-title":"Metabolic effects and safety profile of nebivolol","volume":"38","author":"A C Pessina","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"issue":"01","key":"ref39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1526-4610.2007.00785.x","article-title":"Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?","volume":"48","author":"R Schellenberg","year":"2008","journal-title":"Headache"},{"issue":"01","key":"ref40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1526-4610.1972.hed1201015.x","article-title":"Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis","volume":"12","author":"K Ekbom","year":"1972","journal-title":"Headache"},{"issue":"01","key":"ref41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/ j.1600-0404.1972.tb07532.x","article-title":"Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis","volume":"48","author":"O Sjaastad","year":"1972","journal-title":"Acta Neurol Scand"},{"issue":"04","key":"ref42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"E Perucca","year":"1997","journal-title":"Pharmacol Res"},{"issue":"04","key":"ref43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in migraine prevention: results of a large controlled trial","volume":"61","author":"S D Silberstein","year":"2004","journal-title":"Arch Neurol"},{"issue":"08","key":"ref44","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial","volume":"291","author":"J L Brandes","year":"2004","journal-title":"JAMA"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1526-4610.2005.05183.x","article-title":"Topiramate improves health-related quality of life when used to prevent migraine","volume":"45","author":"M Diamond","year":"2005","journal-title":"Headache"},{"issue":"04","key":"ref46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1528-1157.1975.tb04738.x","article-title":"Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review","volume":"16","author":"D Simon","year":"1975","journal-title":"Epilepsia"},{"issue":"04","key":"ref47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0404.1988.tb03667.x","article-title":"Valproate: a new drug in migraine prophylaxis","volume":"78","author":"K V S\u00f8rensen","year":"1988","journal-title":"Acta Neurol Scand"},{"issue":"02","key":"ref48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1468-2982.1997.1702093.x","article-title":"Possible mechanisms of valproate in migraine prophylaxis","volume":"17","author":"F M Cutrer","year":"1997","journal-title":"Cephalalgia"},{"issue":"06","key":"ref49","doi-asserted-by":"publisher","first-page":"CD010611","DOI":"10.1002\/14651858.CD010611","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","author":"M Linde","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1468-2982.1992.1202081.x","article-title":"Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo","volume":"12","author":"R Hering","year":"1992","journal-title":"Cephalalgia"},{"issue":"03","key":"ref51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/archneur.1995.00540270077022","article-title":"Migraine prophylaxis with divalproex","volume":"52","author":"N T Mathew","year":"1995","journal-title":"Arch Neurol"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1526-4610.1999.3909633.x","article-title":"Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study","volume":"39","author":"S D Silberstein","year":"1999","journal-title":"Headache"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/B978-0-12-397220-0.00006-4","volume-title":"Lamotrigine","author":"K Beattie","year":"2012"},{"issue":"02","key":"ref54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1468-2982.1997.1702109.x","article-title":"Lamotrigine versus placebo in the prophylaxis of migraine with and without aura","volume":"17","author":"T J Steiner","year":"1997","journal-title":"Cephalalgia"},{"issue":"03","key":"ref55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1526-4610.2006.00599.x","article-title":"Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study)","volume":"47","author":"P Gupta","year":"2007","journal-title":"Headache"},{"issue":"01","key":"ref56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1468-2982.1999.1901058.x","article-title":"Lamotrigine in the prophylactic treatment of migraine aura\u2013a pilot study","volume":"19","author":"C Lampl","year":"1999","journal-title":"Cephalalgia"},{"issue":"01","key":"ref57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1468-2982.1999.1901064.x","article-title":"Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study","volume":"19","author":"G D'Andrea","year":"1999","journal-title":"Cephalalgia"},{"issue":"12","key":"ref58","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/jnnp.2005.063750","article-title":"Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura","volume":"76","author":"C Lampl","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"ref59","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/j.1526-4610.2004.04198.x","article-title":"Preventing disturbing migraine aura with lamotrigine: an open study","volume":"44","author":"J Pascual","year":"2004","journal-title":"Headache"},{"issue":"08","key":"ref60","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1526-4610.2001.01150.x","article-title":"Persistent migrainous visual phenomena might be responsive to lamotrigine","volume":"41","author":"W T Chen","year":"2001","journal-title":"Headache"},{"key":"ref61","volume-title":"Levetiracetam","author":"A Kumar","year":"2020"},{"issue":"02","key":"ref62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1358\/mf.2003.25.2.723686","article-title":"The pharmacokinetic characteristics of levetiracetam","volume":"25","author":"P N Patsalos","year":"2003","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"04","key":"ref63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/11204490-000000000-00000","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"K A Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"issue":"02","key":"ref64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neulet.2008.06.076","article-title":"Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients","volume":"442","author":"M de Tommaso","year":"2008","journal-title":"Neurosci Lett"},{"issue":"06","key":"ref65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/WNF.0000000000000005","article-title":"Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India","volume":"36","author":"A Verma","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10194-003-0043-8","article-title":"An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine","volume":"4","author":"V Gallai","year":"2003","journal-title":"The Journal of Headache and Pain"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/187152411794961086","article-title":"Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam","volume":"11","author":"V Pizza","year":"2011","journal-title":"Central Nervous System Agents in Medicinal Chemistry"},{"issue":"06","key":"ref68","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/01.WNF.0000236766.08409.03","article-title":"Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study","volume":"29","author":"F Brighina","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0333102412466968","article-title":"Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis","volume":"33","author":"S Silberstein","year":"2013","journal-title":"Cephalalgia"},{"issue":"01","key":"ref71","first-page":"3","article-title":"Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial","volume":"63","author":"S Zain","year":"2013","journal-title":"J Pak Med Assoc"},{"issue":"07","key":"ref72","first-page":"603","article-title":"Eficacia y seguridad de la gabapentina en el tratamiento preventivo de la migra\u00f1a","volume":"35","author":"M D Jim\u00e9nez-Hern\u00e1ndez","year":"2002","journal-title":"Rev Neurol"},{"issue":"02","key":"ref73","first-page":"783","article-title":"Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study","volume":"17","author":"O Hesami","year":"2018","journal-title":"Iran J Pharm Res"},{"issue":"05","key":"ref74","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10194-011-0338-0","article-title":"Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study","volume":"12","author":"R Pizzolato","year":"2011","journal-title":"J Headache Pain"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.podrm.2015.11.001","article-title":"Carbamazepine","volume":"41","author":"S T Alrashood","year":"2016","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"04","key":"ref76","first-page":"75","article-title":"Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study","volume":"44","author":"H Rompel","year":"1970","journal-title":"S Afr Med J"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/0333102414534325","article-title":"Antiepileptics in migraine prophylaxis: an updated Cochrane review","volume":"35","author":"W M Mulleners","year":"2015","journal-title":"Cephalalgia"},{"key":"ref78","volume-title":"Oxcarbazepine","author":"C V Preuss","year":"2021"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.wnl.0000297551.27191.70","article-title":"Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study","volume":"70","author":"S Silberstein","year":"2008","journal-title":"Neurology"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"J W Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"02","key":"ref81","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s101940200022","article-title":"A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache","volume":"3","author":"K Ghose","year":"2002","journal-title":"J Headache Pain"},{"issue":"02","key":"ref82","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"C E Griffin III","year":"2013","journal-title":"Ochsner J"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1526-4610.1979.hed1906333.x","article-title":"Clonazepam (rivotril) in migraine prophylaxis","volume":"19","author":"P Stensrud","year":"1979","journal-title":"Headache"},{"issue":"04","key":"ref84","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1526-4610.2010.01633.x","article-title":"Clonazepam for refractory headache: three cases illustrative of benefit and risk","volume":"50","author":"M Maizels","year":"2010","journal-title":"Headache"},{"key":"ref85","volume-title":"Zonisamide. [Updated 2019 Oct 21]","author":"R Kadian","year":"2020"},{"issue":"04","key":"ref86","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","article-title":"Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial","volume":"34","author":"S E Mohammadianinejad","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"02","key":"ref88","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1526-4610.2010.01842.x","article-title":"Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study","volume":"51","author":"V Villani","year":"2011","journal-title":"Headache"},{"issue":"06","key":"ref89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.wnf.0000150866.98887.77","article-title":"Open-label zonisamide for refractory migraine","volume":"27","author":"M E Drake Jr","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"891348","DOI":"10.1155\/2014\/891348","article-title":"Efficacy of zonisamide in migraineurs with nonresponse to topiramate","volume":"2014","author":"J Y Chung","year":"2014","journal-title":"BioMed Res Int"},{"issue":"S 01","key":"ref91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1590\/S1516-44461999000500006","article-title":"Psicofarmacologia de antidepressivos","volume":"21","author":"R A Moreno","year":"1999","journal-title":"Rev Bras Psiquiatr"},{"issue":"01","key":"ref93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline in the prophylactic treatment of migraine and chronic daily headache","volume":"51","author":"J R Couch","year":"2011","journal-title":"Headache"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","article-title":"Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs","volume":"31","author":"D W Dodick","year":"2009","journal-title":"Clin Ther"},{"issue":"10","key":"ref95","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3\u2009mg, amitriptyline 25\u2009mg and placebo for migraine prevention","volume":"87","author":"A L Gon\u00e7alves","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"S 03","key":"ref96","first-page":"49","article-title":"Clomipramine in the prevention of migraine","volume":"8","author":"J F Noone","year":"1980","journal-title":"J Int Med Res"},{"issue":"04","key":"ref97","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1590\/S0004-282X2009000600002","article-title":"A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine","volume":"67","author":"R B Domingues","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"ref98","first-page":"1","article-title":"Calcitonin-gene-related peptide pathway mAbs and migraine prevention","author":"K Paemeleire","year":"2018","journal-title":"Current Opinion in Neurology"},{"issue":"03","key":"ref99","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11916-015-0476-1 10.1007\/s11916-015-0476-1","article-title":"TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine","volume":"19","author":"S Walter","year":"2015","journal-title":"Current Pain and Headache Reports"},{"issue":"06","key":"ref100","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies - successful translation from bench to clinic","volume":"14","author":"L Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"ref101","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"P J Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"06","key":"ref102","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"D W Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"09","key":"ref103","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"V L Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"08","key":"ref104","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"V Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"19","key":"ref105","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"D W Dodick","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"ref107","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"D W Dodick","year":"2014","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref108","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"M Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"10","key":"ref109","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","article-title":"Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing","volume":"60","author":"D W Dodick","year":"2020","journal-title":"Headache"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1756441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:56:39Z","timestamp":1682553399000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1756441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":103,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1756441","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}